http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 07 May 2025 08:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/BioVaxys+and+Sona+Nanotech+Enter+Research+Collaboration/24753940.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location> and <location value="LU/ca.ns.halifx" idsrc="xmltag.org" >HALIFAX, NS</location></span>, <span class="legendSpanClass"><chron>May 7, 2025</chron></span> /PRNewswire/ -- <span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys Technology Corp.</span> (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("<b><span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys</span></b>") and <span value="OTC-PINK:SNANF" idsrc="xmltag.org" >Sona Nanotech Inc.</span> (CSE: SONA) (OTC: SNANF) ("<b>Sona</b>") announce today that they have entered into a Research Agreement ("Agreement") to collaborate on the development of new cancer therapeutics based on <span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys'</span> DPX™ Immune Educating Platform ("DPX") in combination with Sona's Targeted Hyperthermia Therapy™ ("THT"), a photothermal cancer therapy that uses highly targeted infrared light to treat solid tumors. The http://www.streetinsider.com/Press+Releases/BioVaxys+and+Sona+Nanotech+Enter+Research+Collaboration/24753940.html Wed, 07 May 2025 08:00:00 -0400 5LB 5LB 5LB 5LB A.12129397 BIOV BIOV BVAXF O.03969270 O.26164643 O.41051729 SNANF SONA http://www.streetinsider.com/Press+Releases/BioVaxys+and+Sona+Nanotech+Enter+Research+Collaboration/24753940.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location> and <location value="LU/ca.ns.halifx" idsrc="xmltag.org" >HALIFAX, NS</location></span>, <span class="legendSpanClass"><chron>May 7, 2025</chron></span> /PRNewswire/ -- <span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys Technology Corp.</span> (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("<b><span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys</span></b>") and <span value="OTC-PINK:SNANF" idsrc="xmltag.org" >Sona Nanotech Inc.</span> (CSE: SONA) (OTC: SNANF) ("<b>Sona</b>") announce today that they have entered into a Research Agreement ("Agreement") to collaborate on the development of new cancer therapeutics based on <span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys'</span> DPX™ Immune Educating Platform ("DPX") in combination with Sona's Targeted Hyperthermia Therapy™ ("THT"), a photothermal cancer therapy that uses highly targeted infrared light to treat solid tumors. The http://www.streetinsider.com/Press+Releases/BioVaxys+and+Sona+Nanotech+Enter+Research+Collaboration/24753940.html Wed, 07 May 2025 08:00:00 -0400 5LB 5LB 5LB 5LB A.12129397 BIOV BIOV BVAXF O.03969270 O.26164643 O.41051729 SNANF SONA http://www.streetinsider.com/Press+Releases/BioVaxys+and+Sona+Nanotech+Enter+Research+Collaboration/24753940.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location> and <location value="LU/ca.ns.halifx" idsrc="xmltag.org" >HALIFAX, NS</location></span>, <span class="legendSpanClass"><chron>May 7, 2025</chron></span> /PRNewswire/ -- <span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys Technology Corp.</span> (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("<b><span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys</span></b>") and <span value="OTC-PINK:SNANF" idsrc="xmltag.org" >Sona Nanotech Inc.</span> (CSE: SONA) (OTC: SNANF) ("<b>Sona</b>") announce today that they have entered into a Research Agreement ("Agreement") to collaborate on the development of new cancer therapeutics based on <span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys'</span> DPX™ Immune Educating Platform ("DPX") in combination with Sona's Targeted Hyperthermia Therapy™ ("THT"), a photothermal cancer therapy that uses highly targeted infrared light to treat solid tumors. The http://www.streetinsider.com/Press+Releases/BioVaxys+and+Sona+Nanotech+Enter+Research+Collaboration/24753940.html Wed, 07 May 2025 08:00:00 -0400 5LB 5LB 5LB 5LB A.12129397 BIOV BIOV BVAXF O.03969270 O.26164643 O.41051729 SNANF SONA http://www.streetinsider.com/Press+Releases/BioVaxys+and+Sona+Nanotech+Enter+Research+Collaboration/24753940.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location> and <location value="LU/ca.ns.halifx" idsrc="xmltag.org" >HALIFAX, NS</location></span>, <span class="legendSpanClass"><chron>May 7, 2025</chron></span> /PRNewswire/ -- <span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys Technology Corp.</span> (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("<b><span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys</span></b>") and <span value="OTC-PINK:SNANF" idsrc="xmltag.org" >Sona Nanotech Inc.</span> (CSE: SONA) (OTC: SNANF) ("<b>Sona</b>") announce today that they have entered into a Research Agreement ("Agreement") to collaborate on the development of new cancer therapeutics based on <span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys'</span> DPX™ Immune Educating Platform ("DPX") in combination with Sona's Targeted Hyperthermia Therapy™ ("THT"), a photothermal cancer therapy that uses highly targeted infrared light to treat solid tumors. The http://www.streetinsider.com/Press+Releases/BioVaxys+and+Sona+Nanotech+Enter+Research+Collaboration/24753940.html Wed, 07 May 2025 08:00:00 -0400 5LB 5LB 5LB 5LB A.12129397 BIOV BIOV BVAXF O.03969270 O.26164643 O.41051729 SNANF SONA http://www.streetinsider.com/Press+Releases/BioVaxys+and+Sona+Nanotech+Enter+Research+Collaboration/24753940.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location> and <location value="LU/ca.ns.halifx" idsrc="xmltag.org" >HALIFAX, NS</location></span>, <span class="legendSpanClass"><chron>May 7, 2025</chron></span> /PRNewswire/ -- <span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys Technology Corp.</span> (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("<b><span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys</span></b>") and <span value="OTC-PINK:SNANF" idsrc="xmltag.org" >Sona Nanotech Inc.</span> (CSE: SONA) (OTC: SNANF) ("<b>Sona</b>") announce today that they have entered into a Research Agreement ("Agreement") to collaborate on the development of new cancer therapeutics based on <span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys'</span> DPX™ Immune Educating Platform ("DPX") in combination with Sona's Targeted Hyperthermia Therapy™ ("THT"), a photothermal cancer therapy that uses highly targeted infrared light to treat solid tumors. The http://www.streetinsider.com/Press+Releases/BioVaxys+and+Sona+Nanotech+Enter+Research+Collaboration/24753940.html Wed, 07 May 2025 08:00:00 -0400 5LB 5LB 5LB 5LB A.12129397 BIOV BIOV BVAXF O.03969270 O.26164643 O.41051729 SNANF SONA http://www.streetinsider.com/Press+Releases/BioVaxys+and+Sona+Nanotech+Enter+Research+Collaboration/24753940.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location> and <location value="LU/ca.ns.halifx" idsrc="xmltag.org" >HALIFAX, NS</location></span>, <span class="legendSpanClass"><chron>May 7, 2025</chron></span> /PRNewswire/ -- <span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys Technology Corp.</span> (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("<b><span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys</span></b>") and <span value="OTC-PINK:SNANF" idsrc="xmltag.org" >Sona Nanotech Inc.</span> (CSE: SONA) (OTC: SNANF) ("<b>Sona</b>") announce today that they have entered into a Research Agreement ("Agreement") to collaborate on the development of new cancer therapeutics based on <span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys'</span> DPX™ Immune Educating Platform ("DPX") in combination with Sona's Targeted Hyperthermia Therapy™ ("THT"), a photothermal cancer therapy that uses highly targeted infrared light to treat solid tumors. The http://www.streetinsider.com/Press+Releases/BioVaxys+and+Sona+Nanotech+Enter+Research+Collaboration/24753940.html Wed, 07 May 2025 08:00:00 -0400 5LB 5LB 5LB 5LB A.12129397 BIOV BIOV BVAXF O.03969270 O.26164643 O.41051729 SNANF SONA http://www.streetinsider.com/Press+Releases/BioVaxys+and+Sona+Nanotech+Enter+Research+Collaboration/24753940.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location> and <location value="LU/ca.ns.halifx" idsrc="xmltag.org" >HALIFAX, NS</location></span>, <span class="legendSpanClass"><chron>May 7, 2025</chron></span> /PRNewswire/ -- <span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys Technology Corp.</span> (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("<b><span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys</span></b>") and <span value="OTC-PINK:SNANF" idsrc="xmltag.org" >Sona Nanotech Inc.</span> (CSE: SONA) (OTC: SNANF) ("<b>Sona</b>") announce today that they have entered into a Research Agreement ("Agreement") to collaborate on the development of new cancer therapeutics based on <span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys'</span> DPX™ Immune Educating Platform ("DPX") in combination with Sona's Targeted Hyperthermia Therapy™ ("THT"), a photothermal cancer therapy that uses highly targeted infrared light to treat solid tumors. The http://www.streetinsider.com/Press+Releases/BioVaxys+and+Sona+Nanotech+Enter+Research+Collaboration/24753940.html Wed, 07 May 2025 08:00:00 -0400 5LB 5LB 5LB 5LB A.12129397 BIOV BIOV BVAXF O.03969270 O.26164643 O.41051729 SNANF SONA http://www.streetinsider.com/Press+Releases/BioVaxys+and+Sona+Nanotech+Enter+Research+Collaboration/24753940.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location> and <location value="LU/ca.ns.halifx" idsrc="xmltag.org" >HALIFAX, NS</location></span>, <span class="legendSpanClass"><chron>May 7, 2025</chron></span> /PRNewswire/ -- <span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys Technology Corp.</span> (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("<b><span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys</span></b>") and <span value="OTC-PINK:SNANF" idsrc="xmltag.org" >Sona Nanotech Inc.</span> (CSE: SONA) (OTC: SNANF) ("<b>Sona</b>") announce today that they have entered into a Research Agreement ("Agreement") to collaborate on the development of new cancer therapeutics based on <span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys'</span> DPX™ Immune Educating Platform ("DPX") in combination with Sona's Targeted Hyperthermia Therapy™ ("THT"), a photothermal cancer therapy that uses highly targeted infrared light to treat solid tumors. The http://www.streetinsider.com/Press+Releases/BioVaxys+and+Sona+Nanotech+Enter+Research+Collaboration/24753940.html Wed, 07 May 2025 08:00:00 -0400 5LB 5LB 5LB 5LB A.12129397 BIOV BIOV BVAXF O.03969270 O.26164643 O.41051729 SNANF SONA http://www.streetinsider.com/Press+Releases/BioVaxys+and+Sona+Nanotech+Enter+Research+Collaboration/24753940.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location> and <location value="LU/ca.ns.halifx" idsrc="xmltag.org" >HALIFAX, NS</location></span>, <span class="legendSpanClass"><chron>May 7, 2025</chron></span> /PRNewswire/ -- <span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys Technology Corp.</span> (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("<b><span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys</span></b>") and <span value="OTC-PINK:SNANF" idsrc="xmltag.org" >Sona Nanotech Inc.</span> (CSE: SONA) (OTC: SNANF) ("<b>Sona</b>") announce today that they have entered into a Research Agreement ("Agreement") to collaborate on the development of new cancer therapeutics based on <span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys'</span> DPX™ Immune Educating Platform ("DPX") in combination with Sona's Targeted Hyperthermia Therapy™ ("THT"), a photothermal cancer therapy that uses highly targeted infrared light to treat solid tumors. The http://www.streetinsider.com/Press+Releases/BioVaxys+and+Sona+Nanotech+Enter+Research+Collaboration/24753940.html Wed, 07 May 2025 08:00:00 -0400 5LB 5LB 5LB 5LB A.12129397 BIOV BIOV BVAXF O.03969270 O.26164643 O.41051729 SNANF SONA http://www.streetinsider.com/Press+Releases/BioVaxys+and+Sona+Nanotech+Enter+Research+Collaboration/24753940.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location> and <location value="LU/ca.ns.halifx" idsrc="xmltag.org" >HALIFAX, NS</location></span>, <span class="legendSpanClass"><chron>May 7, 2025</chron></span> /PRNewswire/ -- <span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys Technology Corp.</span> (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("<b><span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys</span></b>") and <span value="OTC-PINK:SNANF" idsrc="xmltag.org" >Sona Nanotech Inc.</span> (CSE: SONA) (OTC: SNANF) ("<b>Sona</b>") announce today that they have entered into a Research Agreement ("Agreement") to collaborate on the development of new cancer therapeutics based on <span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys'</span> DPX™ Immune Educating Platform ("DPX") in combination with Sona's Targeted Hyperthermia Therapy™ ("THT"), a photothermal cancer therapy that uses highly targeted infrared light to treat solid tumors. The http://www.streetinsider.com/Press+Releases/BioVaxys+and+Sona+Nanotech+Enter+Research+Collaboration/24753940.html Wed, 07 May 2025 08:00:00 -0400 5LB 5LB 5LB 5LB A.12129397 BIOV BIOV BVAXF O.03969270 O.26164643 O.41051729 SNANF SONA http://www.streetinsider.com/Press+Releases/BioVaxys+and+Sona+Nanotech+Enter+Research+Collaboration/24753940.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location> and <location value="LU/ca.ns.halifx" idsrc="xmltag.org" >HALIFAX, NS</location></span>, <span class="legendSpanClass"><chron>May 7, 2025</chron></span> /PRNewswire/ -- <span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys Technology Corp.</span> (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("<b><span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys</span></b>") and <span value="OTC-PINK:SNANF" idsrc="xmltag.org" >Sona Nanotech Inc.</span> (CSE: SONA) (OTC: SNANF) ("<b>Sona</b>") announce today that they have entered into a Research Agreement ("Agreement") to collaborate on the development of new cancer therapeutics based on <span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys'</span> DPX™ Immune Educating Platform ("DPX") in combination with Sona's Targeted Hyperthermia Therapy™ ("THT"), a photothermal cancer therapy that uses highly targeted infrared light to treat solid tumors. The http://www.streetinsider.com/Press+Releases/BioVaxys+and+Sona+Nanotech+Enter+Research+Collaboration/24753940.html Wed, 07 May 2025 08:00:00 -0400 5LB 5LB 5LB 5LB A.12129397 BIOV BIOV BVAXF O.03969270 O.26164643 O.41051729 SNANF SONA http://www.streetinsider.com/Press+Releases/BioVaxys+and+Sona+Nanotech+Enter+Research+Collaboration/24753940.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location> and <location value="LU/ca.ns.halifx" idsrc="xmltag.org" >HALIFAX, NS</location></span>, <span class="legendSpanClass"><chron>May 7, 2025</chron></span> /PRNewswire/ -- <span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys Technology Corp.</span> (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("<b><span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys</span></b>") and <span value="OTC-PINK:SNANF" idsrc="xmltag.org" >Sona Nanotech Inc.</span> (CSE: SONA) (OTC: SNANF) ("<b>Sona</b>") announce today that they have entered into a Research Agreement ("Agreement") to collaborate on the development of new cancer therapeutics based on <span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys'</span> DPX™ Immune Educating Platform ("DPX") in combination with Sona's Targeted Hyperthermia Therapy™ ("THT"), a photothermal cancer therapy that uses highly targeted infrared light to treat solid tumors. The http://www.streetinsider.com/Press+Releases/BioVaxys+and+Sona+Nanotech+Enter+Research+Collaboration/24753940.html Wed, 07 May 2025 08:00:00 -0400 5LB 5LB 5LB 5LB A.12129397 BIOV BIOV BVAXF O.03969270 O.26164643 O.41051729 SNANF SONA http://www.streetinsider.com/Press+Releases/BioVaxys+and+Sona+Nanotech+Enter+Research+Collaboration/24753940.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location> and <location value="LU/ca.ns.halifx" idsrc="xmltag.org" >HALIFAX, NS</location></span>, <span class="legendSpanClass"><chron>May 7, 2025</chron></span> /PRNewswire/ -- <span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys Technology Corp.</span> (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("<b><span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys</span></b>") and <span value="OTC-PINK:SNANF" idsrc="xmltag.org" >Sona Nanotech Inc.</span> (CSE: SONA) (OTC: SNANF) ("<b>Sona</b>") announce today that they have entered into a Research Agreement ("Agreement") to collaborate on the development of new cancer therapeutics based on <span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys'</span> DPX™ Immune Educating Platform ("DPX") in combination with Sona's Targeted Hyperthermia Therapy™ ("THT"), a photothermal cancer therapy that uses highly targeted infrared light to treat solid tumors. The http://www.streetinsider.com/Press+Releases/BioVaxys+and+Sona+Nanotech+Enter+Research+Collaboration/24753940.html Wed, 07 May 2025 08:00:00 -0400 5LB 5LB 5LB 5LB A.12129397 BIOV BIOV BVAXF O.03969270 O.26164643 O.41051729 SNANF SONA http://www.streetinsider.com/PRNewswire/BioVaxys+and+Sona+Nanotech+Enter+Research+Collaboration/24753940.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location> and <location value="LU/ca.ns.halifx" idsrc="xmltag.org" >HALIFAX, NS</location></span>, <span class="legendSpanClass"><chron>May 7, 2025</chron></span> /PRNewswire/ -- <span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys Technology Corp.</span> (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("<b><span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys</span></b>") and <span value="OTC-PINK:SNANF" idsrc="xmltag.org" >Sona Nanotech Inc.</span> (CSE: SONA) (OTC: SNANF) ("<b>Sona</b>") announce today that they have entered into a Research Agreement ("Agreement") to collaborate on the development of new cancer therapeutics based on <span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys'</span> DPX™ Immune Educating Platform ("DPX") in combination with Sona's Targeted Hyperthermia Therapy™ ("THT"), a photothermal cancer therapy that uses highly targeted infrared light to treat solid tumors. The http://www.streetinsider.com/PRNewswire/BioVaxys+and+Sona+Nanotech+Enter+Research+Collaboration/24753940.html Wed, 07 May 2025 08:00:00 -0400 5LB 5LB 5LB 5LB A.12129397 BIOV BIOV BVAXF O.03969270 O.26164643 O.41051729 SNANF SONA http://www.streetinsider.com/PRNewswire/BioVaxys+and+Sona+Nanotech+Enter+Research+Collaboration/24753940.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location> and <location value="LU/ca.ns.halifx" idsrc="xmltag.org" >HALIFAX, NS</location></span>, <span class="legendSpanClass"><chron>May 7, 2025</chron></span> /PRNewswire/ -- <span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys Technology Corp.</span> (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("<b><span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys</span></b>") and <span value="OTC-PINK:SNANF" idsrc="xmltag.org" >Sona Nanotech Inc.</span> (CSE: SONA) (OTC: SNANF) ("<b>Sona</b>") announce today that they have entered into a Research Agreement ("Agreement") to collaborate on the development of new cancer therapeutics based on <span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys'</span> DPX™ Immune Educating Platform ("DPX") in combination with Sona's Targeted Hyperthermia Therapy™ ("THT"), a photothermal cancer therapy that uses highly targeted infrared light to treat solid tumors. The http://www.streetinsider.com/PRNewswire/BioVaxys+and+Sona+Nanotech+Enter+Research+Collaboration/24753940.html Wed, 07 May 2025 08:00:00 -0400 5LB 5LB 5LB 5LB A.12129397 BIOV BIOV BVAXF O.03969270 O.26164643 O.41051729 SNANF SONA http://www.streetinsider.com/PRNewswire/BioVaxys+and+Sona+Nanotech+Enter+Research+Collaboration/24753940.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location> and <location value="LU/ca.ns.halifx" idsrc="xmltag.org" >HALIFAX, NS</location></span>, <span class="legendSpanClass"><chron>May 7, 2025</chron></span> /PRNewswire/ -- <span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys Technology Corp.</span> (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("<b><span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys</span></b>") and <span value="OTC-PINK:SNANF" idsrc="xmltag.org" >Sona Nanotech Inc.</span> (CSE: SONA) (OTC: SNANF) ("<b>Sona</b>") announce today that they have entered into a Research Agreement ("Agreement") to collaborate on the development of new cancer therapeutics based on <span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys'</span> DPX™ Immune Educating Platform ("DPX") in combination with Sona's Targeted Hyperthermia Therapy™ ("THT"), a photothermal cancer therapy that uses highly targeted infrared light to treat solid tumors. The http://www.streetinsider.com/PRNewswire/BioVaxys+and+Sona+Nanotech+Enter+Research+Collaboration/24753940.html Wed, 07 May 2025 08:00:00 -0400 5LB 5LB 5LB 5LB A.12129397 BIOV BIOV BVAXF O.03969270 O.26164643 O.41051729 SNANF SONA http://www.streetinsider.com/PRNewswire/BioVaxys+and+Sona+Nanotech+Enter+Research+Collaboration/24753940.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location> and <location value="LU/ca.ns.halifx" idsrc="xmltag.org" >HALIFAX, NS</location></span>, <span class="legendSpanClass"><chron>May 7, 2025</chron></span> /PRNewswire/ -- <span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys Technology Corp.</span> (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("<b><span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys</span></b>") and <span value="OTC-PINK:SNANF" idsrc="xmltag.org" >Sona Nanotech Inc.</span> (CSE: SONA) (OTC: SNANF) ("<b>Sona</b>") announce today that they have entered into a Research Agreement ("Agreement") to collaborate on the development of new cancer therapeutics based on <span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys'</span> DPX™ Immune Educating Platform ("DPX") in combination with Sona's Targeted Hyperthermia Therapy™ ("THT"), a photothermal cancer therapy that uses highly targeted infrared light to treat solid tumors. The http://www.streetinsider.com/PRNewswire/BioVaxys+and+Sona+Nanotech+Enter+Research+Collaboration/24753940.html Wed, 07 May 2025 08:00:00 -0400 5LB 5LB 5LB 5LB A.12129397 BIOV BIOV BVAXF O.03969270 O.26164643 O.41051729 SNANF SONA http://www.streetinsider.com/PRNewswire/BioVaxys+and+Sona+Nanotech+Enter+Research+Collaboration/24753940.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location> and <location value="LU/ca.ns.halifx" idsrc="xmltag.org" >HALIFAX, NS</location></span>, <span class="legendSpanClass"><chron>May 7, 2025</chron></span> /PRNewswire/ -- <span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys Technology Corp.</span> (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("<b><span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys</span></b>") and <span value="OTC-PINK:SNANF" idsrc="xmltag.org" >Sona Nanotech Inc.</span> (CSE: SONA) (OTC: SNANF) ("<b>Sona</b>") announce today that they have entered into a Research Agreement ("Agreement") to collaborate on the development of new cancer therapeutics based on <span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys'</span> DPX™ Immune Educating Platform ("DPX") in combination with Sona's Targeted Hyperthermia Therapy™ ("THT"), a photothermal cancer therapy that uses highly targeted infrared light to treat solid tumors. The http://www.streetinsider.com/PRNewswire/BioVaxys+and+Sona+Nanotech+Enter+Research+Collaboration/24753940.html Wed, 07 May 2025 08:00:00 -0400 5LB 5LB 5LB 5LB A.12129397 BIOV BIOV BVAXF O.03969270 O.26164643 O.41051729 SNANF SONA http://www.streetinsider.com/PRNewswire/BioVaxys+and+Sona+Nanotech+Enter+Research+Collaboration/24753940.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location> and <location value="LU/ca.ns.halifx" idsrc="xmltag.org" >HALIFAX, NS</location></span>, <span class="legendSpanClass"><chron>May 7, 2025</chron></span> /PRNewswire/ -- <span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys Technology Corp.</span> (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("<b><span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys</span></b>") and <span value="OTC-PINK:SNANF" idsrc="xmltag.org" >Sona Nanotech Inc.</span> (CSE: SONA) (OTC: SNANF) ("<b>Sona</b>") announce today that they have entered into a Research Agreement ("Agreement") to collaborate on the development of new cancer therapeutics based on <span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys'</span> DPX™ Immune Educating Platform ("DPX") in combination with Sona's Targeted Hyperthermia Therapy™ ("THT"), a photothermal cancer therapy that uses highly targeted infrared light to treat solid tumors. The http://www.streetinsider.com/PRNewswire/BioVaxys+and+Sona+Nanotech+Enter+Research+Collaboration/24753940.html Wed, 07 May 2025 08:00:00 -0400 5LB 5LB 5LB 5LB A.12129397 BIOV BIOV BVAXF O.03969270 O.26164643 O.41051729 SNANF SONA http://www.streetinsider.com/PRNewswire/BioVaxys+and+Sona+Nanotech+Enter+Research+Collaboration/24753940.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location> and <location value="LU/ca.ns.halifx" idsrc="xmltag.org" >HALIFAX, NS</location></span>, <span class="legendSpanClass"><chron>May 7, 2025</chron></span> /PRNewswire/ -- <span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys Technology Corp.</span> (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("<b><span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys</span></b>") and <span value="OTC-PINK:SNANF" idsrc="xmltag.org" >Sona Nanotech Inc.</span> (CSE: SONA) (OTC: SNANF) ("<b>Sona</b>") announce today that they have entered into a Research Agreement ("Agreement") to collaborate on the development of new cancer therapeutics based on <span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys'</span> DPX™ Immune Educating Platform ("DPX") in combination with Sona's Targeted Hyperthermia Therapy™ ("THT"), a photothermal cancer therapy that uses highly targeted infrared light to treat solid tumors. The http://www.streetinsider.com/PRNewswire/BioVaxys+and+Sona+Nanotech+Enter+Research+Collaboration/24753940.html Wed, 07 May 2025 08:00:00 -0400 5LB 5LB 5LB 5LB A.12129397 BIOV BIOV BVAXF O.03969270 O.26164643 O.41051729 SNANF SONA http://www.streetinsider.com/PRNewswire/BioVaxys+and+Sona+Nanotech+Enter+Research+Collaboration/24753940.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location> and <location value="LU/ca.ns.halifx" idsrc="xmltag.org" >HALIFAX, NS</location></span>, <span class="legendSpanClass"><chron>May 7, 2025</chron></span> /PRNewswire/ -- <span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys Technology Corp.</span> (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("<b><span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys</span></b>") and <span value="OTC-PINK:SNANF" idsrc="xmltag.org" >Sona Nanotech Inc.</span> (CSE: SONA) (OTC: SNANF) ("<b>Sona</b>") announce today that they have entered into a Research Agreement ("Agreement") to collaborate on the development of new cancer therapeutics based on <span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys'</span> DPX™ Immune Educating Platform ("DPX") in combination with Sona's Targeted Hyperthermia Therapy™ ("THT"), a photothermal cancer therapy that uses highly targeted infrared light to treat solid tumors. The http://www.streetinsider.com/PRNewswire/BioVaxys+and+Sona+Nanotech+Enter+Research+Collaboration/24753940.html Wed, 07 May 2025 08:00:00 -0400 5LB 5LB 5LB 5LB A.12129397 BIOV BIOV BVAXF O.03969270 O.26164643 O.41051729 SNANF SONA http://www.streetinsider.com/PRNewswire/BioVaxys+and+Sona+Nanotech+Enter+Research+Collaboration/24753940.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location> and <location value="LU/ca.ns.halifx" idsrc="xmltag.org" >HALIFAX, NS</location></span>, <span class="legendSpanClass"><chron>May 7, 2025</chron></span> /PRNewswire/ -- <span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys Technology Corp.</span> (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("<b><span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys</span></b>") and <span value="OTC-PINK:SNANF" idsrc="xmltag.org" >Sona Nanotech Inc.</span> (CSE: SONA) (OTC: SNANF) ("<b>Sona</b>") announce today that they have entered into a Research Agreement ("Agreement") to collaborate on the development of new cancer therapeutics based on <span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys'</span> DPX™ Immune Educating Platform ("DPX") in combination with Sona's Targeted Hyperthermia Therapy™ ("THT"), a photothermal cancer therapy that uses highly targeted infrared light to treat solid tumors. The http://www.streetinsider.com/PRNewswire/BioVaxys+and+Sona+Nanotech+Enter+Research+Collaboration/24753940.html Wed, 07 May 2025 08:00:00 -0400 5LB 5LB 5LB 5LB A.12129397 BIOV BIOV BVAXF O.03969270 O.26164643 O.41051729 SNANF SONA http://www.streetinsider.com/PRNewswire/BioVaxys+and+Sona+Nanotech+Enter+Research+Collaboration/24753940.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location> and <location value="LU/ca.ns.halifx" idsrc="xmltag.org" >HALIFAX, NS</location></span>, <span class="legendSpanClass"><chron>May 7, 2025</chron></span> /PRNewswire/ -- <span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys Technology Corp.</span> (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("<b><span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys</span></b>") and <span value="OTC-PINK:SNANF" idsrc="xmltag.org" >Sona Nanotech Inc.</span> (CSE: SONA) (OTC: SNANF) ("<b>Sona</b>") announce today that they have entered into a Research Agreement ("Agreement") to collaborate on the development of new cancer therapeutics based on <span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys'</span> DPX™ Immune Educating Platform ("DPX") in combination with Sona's Targeted Hyperthermia Therapy™ ("THT"), a photothermal cancer therapy that uses highly targeted infrared light to treat solid tumors. The http://www.streetinsider.com/PRNewswire/BioVaxys+and+Sona+Nanotech+Enter+Research+Collaboration/24753940.html Wed, 07 May 2025 08:00:00 -0400 5LB 5LB 5LB 5LB A.12129397 BIOV BIOV BVAXF O.03969270 O.26164643 O.41051729 SNANF SONA http://www.streetinsider.com/PRNewswire/BioVaxys+and+Sona+Nanotech+Enter+Research+Collaboration/24753940.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location> and <location value="LU/ca.ns.halifx" idsrc="xmltag.org" >HALIFAX, NS</location></span>, <span class="legendSpanClass"><chron>May 7, 2025</chron></span> /PRNewswire/ -- <span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys Technology Corp.</span> (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("<b><span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys</span></b>") and <span value="OTC-PINK:SNANF" idsrc="xmltag.org" >Sona Nanotech Inc.</span> (CSE: SONA) (OTC: SNANF) ("<b>Sona</b>") announce today that they have entered into a Research Agreement ("Agreement") to collaborate on the development of new cancer therapeutics based on <span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys'</span> DPX™ Immune Educating Platform ("DPX") in combination with Sona's Targeted Hyperthermia Therapy™ ("THT"), a photothermal cancer therapy that uses highly targeted infrared light to treat solid tumors. The http://www.streetinsider.com/PRNewswire/BioVaxys+and+Sona+Nanotech+Enter+Research+Collaboration/24753940.html Wed, 07 May 2025 08:00:00 -0400 5LB 5LB 5LB 5LB A.12129397 BIOV BIOV BVAXF O.03969270 O.26164643 O.41051729 SNANF SONA http://www.streetinsider.com/PRNewswire/BioVaxys+and+Sona+Nanotech+Enter+Research+Collaboration/24753940.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location> and <location value="LU/ca.ns.halifx" idsrc="xmltag.org" >HALIFAX, NS</location></span>, <span class="legendSpanClass"><chron>May 7, 2025</chron></span> /PRNewswire/ -- <span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys Technology Corp.</span> (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("<b><span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys</span></b>") and <span value="OTC-PINK:SNANF" idsrc="xmltag.org" >Sona Nanotech Inc.</span> (CSE: SONA) (OTC: SNANF) ("<b>Sona</b>") announce today that they have entered into a Research Agreement ("Agreement") to collaborate on the development of new cancer therapeutics based on <span value="CNSX:BIOV" idsrc="xmltag.org" >BioVaxys'</span> DPX™ Immune Educating Platform ("DPX") in combination with Sona's Targeted Hyperthermia Therapy™ ("THT"), a photothermal cancer therapy that uses highly targeted infrared light to treat solid tumors. The http://www.streetinsider.com/PRNewswire/BioVaxys+and+Sona+Nanotech+Enter+Research+Collaboration/24753940.html Wed, 07 May 2025 08:00:00 -0400 5LB 5LB 5LB 5LB A.12129397 BIOV BIOV BVAXF O.03969270 O.26164643 O.41051729 SNANF SONA